Abstract
Given the high proportion of patients with asthma who remain uncontrolled despite controller treatment, there remains a need for the development of more effective treatment options with a proven safety and tolerability profile. Recently, asthma guidelines have evolved to incorporate new therapies, including long-acting muscarinic antagonists (LAMAs) and biologics. Here we focus on the safety profile of tiotropium, a LAMA, using data from the large-scale UniTinA-asthma® clinical trial program, which investigated the use of tiotropium in over 6000 patients with asthma who remained symptomatic despite receiving inhaled corticosteroids (ICS) maintenance therapy, with or without other adjunct therapies. The large number of patients included allows robust analysis of safety and tolerability. Overall, a similar incidence of patients reporting any adverse event (AE) was observed in the tiotropium (5 µg and 2.5 µg) and placebo groups. Asthma worsening, decreased peak expiratory flow, and upper respiratory tract infections were the most frequently reported AEs. Serious AEs (SAEs) and investigator-defined drug-related AEs were infrequently reported across all treatment groups, including the placebo group, and there were no deaths in any s...Continue Reading
References
Jul 18, 2006·Thorax·R G BarrF S F Ram
Mar 24, 2007·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Jordana K SchmierGregory B Diette
Sep 25, 2008·JAMA : the Journal of the American Medical Association·Sonal SinghCurt D Furberg
Jul 14, 2009·Chest·Bartolome CelliDonald P Tashkin
Aug 3, 2011·The Journal of Allergy and Clinical Immunology·Eric D BatemanLeonardo M Fabbri
Sep 4, 2012·The New England Journal of Medicine·Huib A M KerstjensEric D Bateman
Mar 4, 2014·Therapeutic Advances in Chronic Disease·Khuder AlaghaPascal Chanez
Jun 13, 2014·NPJ Primary Care Respiratory Medicine·David PriceThys van der Molen
Feb 16, 2015·The Lancet. Respiratory Medicine·Huib A M KerstjensEric D Bateman
Apr 22, 2015·PloS One·Ken OhtaMitsuru Adachi
Jun 3, 2015·Respiratory Research·Donald P TashkinMarc Decramer
Nov 14, 2015·The Journal of Allergy and Clinical Immunology. in Practice·Pierluigi PaggiaroEmilio Pizzichini
Mar 11, 2016·The Journal of Allergy and Clinical Immunology·Eckard HamelmannAttilio L Boner
Sep 1, 2016·Respiratory Medicine·Ronald DahlEric D Bateman
Oct 12, 2016·BMC Pulmonary Medicine·Ronald Dahl, Alan Kaplan
Nov 5, 2016·The European Respiratory Journal·Eckard HamelmannAttilio L Boner
Feb 13, 2017·The Journal of Allergy and Clinical Immunology·Stanley J SzeflerEckard Hamelmann
Jun 15, 2017·Respiratory Medicine·David M HalpinRichard K Russell
Jul 12, 2017·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Gustavo J Rodrigo, Hugo Neffen
Jan 24, 2018·The Lancet. Respiratory Medicine·Elianne J L E VrijlandtHans Bisgaard
Jan 26, 2018·Drugs·Eckard Hamelmann, Stanley J Szefler
May 12, 2018·The Journal of Allergy and Clinical Immunology. in Practice·Christian VogelbergEckard Hamelmann
Citations
Aug 24, 2019·Medicine·Qi ShiYoulin Li
Jul 21, 2020·Expert Opinion on Pharmacotherapy·Timothy E AlbertsonSusan Murin
Mar 5, 2020·Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia·Marcia Margaret Menezes PizzichiniAlberto Cukier
Dec 5, 2019·The New England Journal of Medicine·Sandra C Christiansen, Bruce L Zuraw
Sep 9, 2020·Postgraduate Medicine·Alan Kaplan, Ku-Lang Chang
Dec 10, 2020·Clinical and Molecular Allergy : CMA·Federica GaniGianenrico Senna
Feb 11, 2021·European Journal of Internal Medicine·Alberto PapiDave Singh
Mar 24, 2020·Journal of Medicinal Chemistry·Oliver FischerMarkus Rolf Heinrich